Circulating tumor cells as emerging tumor biomarkers in breast cancer

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 10, 2011, Pages 1579-1590

  Lianidou, Evi S ^a   Markou, Athina ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

breast cancer; circulating tumor cells; liquid biopsy; micrometastasis; mimal residual disease; tumor biomarkers

Indexed keywords

ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CD45 ANTIGEN; CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; MAMMAGLOBIN; MESSENGER RNA; MICRORNA; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN; TUMOR MARKER; VASCULOTROPIN RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVANCED CANCER; ANGIOGENESIS; BIOPSY; BLOOD; BONE METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RELAPSE; CANCER STAGING; CANCER THERAPY; CELL ISOLATION; CELL VIABILITY; CENTRIFUGATION; CIRCULATING TUMOR CELL; CLINICAL TRIAL (TOPIC); CYTOLOGY; DISEASE COURSE; DISEASE FREE SURVIVAL; DORMANCY; DRUG EFFICACY; EARLY CANCER; ENRICHMENT CULTURE; EPITHELIAL MESENCHYMAL TRANSITION; FOLLOW UP; GENE EXPRESSION; GENOME ANALYSIS; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; INFLAMMATORY BREAST CANCER; LEUKOCYTE; LIQUID BIOPSY; MICROFLUIDICS; MICROMETASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; NUCLEIC ACID ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT MONITORING; PERSONALIZED MEDICINE; POSTOPERATIVE PERIOD; PREDICTION; PREDICTIVE VALUE; PREVALENCE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; SOLID TUMOR; TREATMENT FAILURE; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASTIC CELLS, CIRCULATING;

EID: 80054905062     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.628     Document Type: Review

References (123)

1. Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Med J Aust 1869;14:146-7.
2. Fidler IJ. The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003;3:453-8. (Pubitemid 37328849)
3. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005;353:793-802. (Pubitemid 41215488)
4. Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis Ch, Apostolaki S, et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic significance. J Clin Oncol 2002;20:3404-12.
5. Xenidis N, Vlachonikolis I, Mavroudis D, Perraki M, Stathopoulou A, Lianidou E, et al. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 2003;14:849-55. (Pubitemid 36827199)
6. Xenidis N, Perraki M, Kafousi M, Apostolaki S, Lianidou ES, Georgoulias V, et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 2006;24:3756-62. (Pubitemid 46622314)
7. Ignatiadis M, Kallergi G, Ntoulia M, Lianidou E, Georgoulias V, Mavroudis D, et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res 2008;14:2593-600.
8. Ignatiadis M, Xenidis N, Perraki M, Lianidou E, Sotiriou C, Georgoulias V, et al. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol 2007;25:5194-202. (Pubitemid 350232250)
9. Cristofanilli M, Budd GT, Ellis MJ, Allard WJ, Terstappen LW, Hayes DF, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351:781-91. (Pubitemid 39095313)
10. Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Georgoulias V, Mavroudis D, et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 2009;27:2177-84.
11. Sleijfer S, Gratama J-M, Sieuwerts AM, Kraan J, Martens JW, Foekens JA. Circulating tumour cell detection on its way to routine diagnostic implementation? Eur J Cancer 2007;43: 2645-50. (Pubitemid 350151847)
12. Hayes DF, Smerage JR. Is there a role for circulating tumor cells in the management of breast cancer? Clin Cancer Res 2008;14:3646-50.
13. Pantel K, Alix-Panabieres C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 2009;16:339-51.
14. Pantel K, Riethdorf S. Pathology: Are circulating tumor cells predictive of overall survival? Nature Rev Clin Oncol 2009; 6:190-1.
15. de Bono JS, Scher HI, Montgomery RB, Doyle GV, Terstappen LW, Pienta KJ, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-9.
16. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer. A reanalysis of IMMC38 trial data. Lancet Oncol 2009;10:233-9.
17. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Uhr J, et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004;101:9393-8. (Pubitemid 38812885)
18. Bozionellou V, Mavroudis D, Perraki M, Stathopoulou A, Lianidou E, Georgoulias V, et al. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res 2004;10:8185-94. (Pubitemid 40053377)
19. Lianidou ES, Mavroudis D, Sotiropoulou G, Agelaki S, Pantel K. What's new on circulating tumor cells? A meeting report. Breast Cancer Res 2010;12:307.
20. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007;7:834-46. (Pubitemid 350006258)
21. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004;10:8152-62. (Pubitemid 40053373)
22. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, et al. Tumor self-seeding by circulating cancer cells. Cell 2009;139:1315-26.
23. Aguirre-Ghiso JA. On the theory of tumor self-seeding: Implications for metastasis progression in humans. Br Cancer Res 2010;12:304.
24. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009;9:302-12.
25. Stoecklein NH, Klein CA. Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int J Cancer 2010;126:589-98.
26. Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008;13:58-68. (Pubitemid 350309740)
27. Fuhrmann C, Schmidt-Kittler O, Stoecklein NH, Petat-Dutter K, Vay C, Bockler K, et al. High-resolution array comparative genomic hybridization of single micrometastatic tumor cells. Nucleic Acids Res 2008;36:e39.
28. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9:265-73.
29. Metge BJ, Frost AR, King JA, Dyess DL, Welch DR, Samant RS, et al. Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer. Clin Exp Metastasis 2008;25: 753-63.
30. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 2009;69:1279-83.
31. Vaidya KS, Harihar S, Phadke PA, Stafford LJ, Hurst DR, Hicks DG, et al. Breast cancer metastasis suppressor-1 differentially modulates growth factor signaling. J Biol Chem 2008; 283:28354-60.
32. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7: 131-42. (Pubitemid 43278296)
33. Le XF, Merchant O, Bast RC, Calin GA. The roles of micro-RNAs in the cancer invasion-metastasis cascade. Cancer Microenviron 2010;3:137-47.
34. Sotiropoulou G, Pampalakis G, Lianidou E, Mourelatos Z. Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA 2009;15:1443-61.
35. Metias SM, Lianidou E, Yousef GM. MicroRNAs in clinical oncology: At the crossroads between promises and problems. J Clin Pathol 2009;62:771-6.
36. Tibbe AG, Miller MC, Terstappen LW. Statistical considerations for enumeration of circulating tumor cells. Cytometry A 2007;71:154-62. (Pubitemid 46355340)
37. Fehm T, Solomayer EF, Meng S, Tucker T, Lane N, Wang J, et al. Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. Cytotherapy 2005; 7:171-85. (Pubitemid 40872753)
38. Königsberg R, Obermayr E, Bises G, Pfeiler G, Gneist M,Wrba F, et al. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Epub Acta Oncol 2011;50:700-10.
39. Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009;101:61-6.
40. Mostert B, Kraan J, Bolt-de Vries J, van der Spoel P, Sieuwerts AM, Schutte M, et al. Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Res Treat 2011;127:33-41.
41. Schindlbeck C, Stellwagen J, Jeschke U, Karsten U, Rack B, Janni W, et al. Immunomagnetic enrichment of disseminated tumor cells in bone marrow and blood of breast cancer patients by the Thomsen-Friedenreich-Antigen. Clin Exp Metastasis 2008;25:233-40.
42. Deng G, Herrler M, Burgess D, Manna E, Krag D, Burke JF. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res 2008;10:R69.
43. Markou A, Strati A, Malamos N, Georgoulias V, Lianidou ES. Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. Clin Chem 2011;57:421-30.
44. Lin H, Balic M, Zheng S, Datar R, Cote RJ. Disseminated and circulating tumor cells: Role in effective cancer management. Crit Rev Oncol Hematol 2011;77:1-11.
45. Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schütze K, et al. Isolation by size of epithelial tumor cells: A new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol 2000;156:57-63. (Pubitemid 30644439)
46. Pinzani P, Salvadori B, Simi L, Bianchi S, Distante V, Cataliotti L, et al. Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: Correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection. Hum Pathol 2006;37:711-8. (Pubitemid 43956539)
47. Zheng S, Lin H, Liu JQ, Balic M, Datar R, Cote RJ, et al. Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chromatogr A 2007;1162:154-61. (Pubitemid 47187403)
48. Lin HK, Zheng S, Williams AJ, Balic M, Groshen S, Scher HI, et al. Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res 2010; 16:5011-8.
49. Zheng S, Lin HK, Lu B, Williams A, Datar R, Cote RJ, et al. 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed Microdevices 2011;13:203-13.
50. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007;450:1235-9.
51. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci USA 2010;107:18392-7.
52. Adams AA, Okagbare PI, Feng J, Hupert ML, Patterson D, Göttert J, et al. Highly efficient circulating tumor cell isolation from whole blood and label-free enumeration using polymerbased microfluidics with an integrated conductivity sensor. J Am Chem Soc 2008;130:8633-41. (Pubitemid 351962496)
53. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008;8:329-40. (Pubitemid 351596394)
54. Pachmann K, Heiss P, Demel U, Tilz G. Detection and quantification of small numbers of circulating tumour cells in peripheral blood using laser scanning cytometer (LSC). Clin Chem Lab Med 2001;39:811-7. (Pubitemid 32899131)
55. Pachmann K, Clement JH, Schneider CP, Willen B, Camara O, Pachmann U, et al. Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin Chem Lab Med 2005;43:617-27. (Pubitemid 41460612)
56. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006;12:6403-9. (Pubitemid 44799711)
57. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006; 12:4218-24.
58. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: A validation study of the cell search system. Clin Cancer Res 2007;13:920-8. (Pubitemid 46340368)
59. Miller MC, Doyle GV, Terstappen LW. Significance of circulating tumor cells detected by the cellsearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol 2010;2010:617421.
60. Balic M, Rapp N, Stanzer S, Lin H, Strutz J, Szkandera J, et al. Novel immunofluorescence protocol for multimarker assessment of putative disseminating breast cancer stem cells. Appl Immunohistochem Mol Morphol 2011;19:33-40.
61. Slade MJ, Smith BM, Sinnett HD, Cross NC, Coombes RC. Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer. J Clin Oncol 1999;17:870-9. (Pubitemid 29109317)
62. Stathopoulou A, Angelopoulou K, Perraki M, Georgoulias V, Malamos N, Lianidou E. Quantitative RT-PCR luminometric hybridization assay with an RNA internal standard for cytokeratin-19 mRNA in peripheral blood of patients with breast cancer. Clin Biochem 2001;34:651-9. (Pubitemid 34159357)
63. Stathopoulou A, Gizi A, Perraki M, Apostolaki S, Malamos N, Mavroudis D, et al. Real-time quantification of CK-19 mRNApositive cells in peripheral blood of breast cancer patients using the light cycler system. Clin Cancer Res 2003;9:5145-51. (Pubitemid 37413564)
64. Stathopoulou A, Ntoulia M, Perraki M, Apostolaki S, Mavroudis D, Malamos N, et al. A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. Int J Cancer 2006;119:1654-9. (Pubitemid 44258772)
65. Fehm T, Braun S, Muller V, Janni W, Naume B, Pantel K, et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 2006;107:885-92. (Pubitemid 44291136)
66. Ring AE, Zabaglo L, Ormerod MG, Smith IE, Dowsett M. Detection of circulating epithelial cells in the blood of patients with breast cancer. Comparison of three techniques. Br J Cancer 2005;92:906-12. (Pubitemid 40462638)
67. Reinholz MM, Nibbe A, Jonart LM, Houghton R, Zehentner B, Roche PC, et al. Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer. Clin Cancer Res 2005;11:3722-32. (Pubitemid 40685589)
68. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009;11: R46.
69. Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer EF, Wallwiener D, et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RTPCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 2009;11:R59.
70. Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, Mostert B, Martens JW, et al. Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res Treat 2009;118:455-68.
71. Xi L, Nicastri DG, El-Hefnawy T, Hughes SJ, Luketich JD, Godfrey TE. Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clin Chem 2007;53:1206-15. (Pubitemid 47020975)
72. Alix-Panabières C, Vendrell JP, Slijper M, Pellé O, Barbotte E, Mercier G, et al. Full-length cytokeratin-19 is released by human tumor cells: A potential role in metastatic progression of breast cancer. Breast Cancer Res 2009;11:R39.
73. Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: A prospective, multicenter trial. Breast Cancer Res Treat 2010;124:403-12.
74. Kraan J, Sleijfer S, Strijbos MH, Ignatiadis M, Peeters D, Pierga JY, et al. External quality assurance of circulating tumor cell enumeration using the CellSearch(+) system: A feasibility study. Cytometry B Clin Cytom 2011;80:112-8.
75. Balic M, Dandachi N, Hofmann G, Samonigg H, Loibner H, Obwaller A, et al. Comparison of two methods for enumerating circulating tumor cells in carcinoma patients. Cytometry B Clin Cytom 2005;68:25-30. (Pubitemid 41566360)
76. Punnoose EA, Atwal SK, Spoerke JM, Savage H, Pandita A, Yeh RF, et al. Molecular biomarker analyses using circulating tumor cells. PLoS One 2010;5:e12517.
77. Smith BM, Slade MJ, English J, Graham H, Lüchtenborg M, Sinnett HD, et al. Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: Comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J Clin Oncol 2000;18:1432-9. (Pubitemid 30205388)
78. Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S, et al. Comparison of assay methods for detection of circulating tumor cells (CTCs) in metastatic breast cancer (MBC): AdnaGen AdnaTest BreastCancer Select/Detect versus Veridex CellSearch system. Int J Cancer Epub 2011 Apr 5.
79. Van der Auwera I, Peeters D, Benoy IH, Elst HJ, Van Laere SJ, Prové A, et al. Circulating tumour cell detection: A direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer 2010;102:276-84.
80. Schmitt M, Foekens JA. Circulating tumor cells in blood of primary breast cancer patients assessed by a novel RT-PCR test kit and comparison with status of bone marrow-disseminated tumor cells. Breast Cancer Res 2009;11:109.
81. Ignatiadis M, Georgoulias V, Mavroudis D. Micrometastatic disease in breast cancer: Clinical implications. Eur J Cancer 2008;44:2726-36.
82. Daskalaki A, Agelaki S, Perraki M, Apostolaki S, Xenidis N, Stathopoulos E, et al. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Br J Cancer 2009;101:589-97.
83. Pierga JY, Bidard FC, Mathiot C, Brain E, Delaloge S, Giachetti S, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 2008;14:7004-10.
84. Bidard FC, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P, et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 2010;21:729-33.
85. Rack B, Schindlbeck C, Andergassen U, Schneeweiss A, Zwingers T, Lichtenegger W, et al. Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: The SUCCESS trial. J Clin Oncol 2010;28:7s.
86. Nakamura S, Yagata H, Ohno S, Yamaguchi H, Iwata H, Tsunoda N, et al. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Br Cancer 2010;17:199-204.
87. Gaforio JJ, Serrano MJ, Sanchez-Rovira P, Sirvent A, Delgado-Rodriguez M, Campos M, et al. Detection of breast cancer cells in the peripheral blood is positively correlated with estrogenreceptor status and predicts for poor prognosis. Int J Cancer 2003;107:984-90. (Pubitemid 37429841)
88. Wülfing P, Borchard J, Buerger H, Heidl S, Zänker KS, Kiesel L, et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 2006;12:1715-20.
89. Ntoulia M, Stathopoulou A, Ignatiadis M, Malamos N, Mavroudis D, Georgoulias V, et al. Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. Clin Biochem 2006;39:879-87. (Pubitemid 44363084)
90. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, et al. Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005;23:1420-30.
91. De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, et al. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol 2010;21:33-9.
92. Nakagawa T, Martinez SR, Goto Y, Koyanagi K, Kitago M, Shingai T, et al. Detection of circulating tumor cells in earlystage breast cancer metastasis to axillary lymph nodes. Clin Cancer Res 2007;13:4105-10. (Pubitemid 47105972)
93. Slade MJ, Payne R, Riethdorf S, Ward B, Zaidi SA, Stebbing J, et al. Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. Br J Cancer 2009;100:160-6.
94. Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, et al. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer 2010; 116:3330-7.
95. Sandri MT, Zorzino L, Cassatella MC, Bassi F, Luini A, Casadio C, et al. Changes in circulating tumor cell detection in patients with localized breast cancer before and after surgery. Ann Surg Oncol 2010;17:1539-45.
96. Biggers B, Knox S, Grant M, Kuhn J, Nemunatitis J, Fisher T, et al. Circulating tumor cells in patients undergoing surgery for primary breast cancer: Preliminary results of a pilot study. Ann Surg Oncol 2009;16:969-71.
97. Mego M, De Giorgi U, Broglio K, Dawood S, Valero V, Andreopoulou E, et al. Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients. Br J Cancer 2009;101:1813-6.
98. Mego M, De Giorgi U, Hsu L, Ueno NT, Valero V, Jackson S, et al. Circulating tumor cells in metastatic inflammatory breast cancer. Ann Oncol 2009;20:1824-8.
99. Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, Ottaviano YL, et al. Circulating tumor cells: A useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009;27:5153-9.
100. Giordano A, Giuliano M, Hsu L, Handy BC, Ueno NT, Andreopoulou E, et al. Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): Correlation with immunohistochemically defined molecular subtypes and metastatic disease sites. J Clin Oncol 2010;28:7s (ASCO abstr 1000).
101. Bidard FC, Mathiot C, Degeorges A, Etienne-Grimaldi MC, Delva R, Pivot X, et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 2010;21:1765-71.
102. Gazzaniga P, Naso G, Gradilone A, Cortesi E, Gandini O, Gianni W, et al. Chemosensitivity profile assay of circulating cancer cells: Prognostic and predictive value in epithelial tumors. Int J Cancer 2010;126:2437-47.
103. Gradilone A, Naso G, Raimondi C, Cortesi E, Gandini O, Vincenzi B, et al. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): Prognosis, drug resistance and phenotypic characterization. Ann Oncol 2011;22:86-92.
104. Serrano MJ, Sánchez-Rovira P, Delgado-Rodriguez M, Gaforio JJ. Detection of circulating tumor cells in the context of treatment: Prognostic value in breast cancer. Cancer Biol Ther 2009;8:671-5.
105. Riethdorf S, Müller V, Zhang L, Rau T, Loibl S, Komor M, et al. Detection and HER2 expression of circulating tumor cells: Prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010; 16:2634-45.
106. Fehm T, Müller V, Alix-Panabières C, Pantel K. Micrometastatic spread in breast cancer: Detection, molecular characterization and clinical relevance. Breast Cancer Res 2008;10 (Suppl 1):S1.
107. Mego M, Mani SA, Cristofanilli M. Molecular mechanisms of metastasis in breast cancer-clinical applications. Nat Rev Clin Oncol 2010;7:693-701.
108. Riethdorf S, Pantel K. Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells. Ann NY Acad Sci 2010;1210:66-77.
109. Kasimir-Bauer S. Circulating tumor cells as markers for cancer risk assessment and treatment monitoring. Mol Diagn Ther 2009;13:209-15.
110. Tewes M, Aktas B, Welt A, Mueller S, Hauch S, Kimmig R, et al. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: An option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat 2009;115:581-90.
111. Cao S, Li Y, Li J, Li CF, Zhang W, Yang ZQ, et al. Quantitative determination of HER2 expression by confocal microscopy assay in CTCs of breast cancer. Oncol Rep 2010;23: 423-8.
112. Krawczyk N, Banys M, Neubauer H, Solomayer EF, Gall C, Hahn M, et al. HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res 2009;29:4019-24.
113. Ignatiadis M, Rothé F, Chaboteaux C, Durbecq V, Rouas G, Criscitiello C, et al. HER2-positive circulating tumor cells in breast cancer. PLoS One 2011;6:e15624.
114. Apostolaki S, Perraki M, Pallis A, Bozionelou V, Agelaki S, Kanellou P, et al. Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: Evaluation of their clinical relevance. Ann Oncol 2007;18: 851-8. (Pubitemid 47054081)
115. Munzone E, Nolé F, Goldhirsch A, Botteri E, Esposito A, Zorzino L, et al. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin Breast Cancer 2010;10:392-7.
116. Flores LM, Kindelberger DW, Ligon AH, Capelletti M, Fiorentino M, Loda M, et al. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br J Cancer 2010;102:1495-502.
117. Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, Biagioni C, et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 2009;118:523-30.
118. Kallergi G, Markomanolaki H, Giannoukaraki V, Papadaki MA, Strati A, Lianidou ES, et al. Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Res 2009;11:R84.
119. Payne RE, Yagüe E, Slade MJ, Apostolopoulos C, Jiao LR, Ward B, et al. Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. Pharmacogenomics 2009;10:51-7.
120. Liu Z, Fusi A, Schmittel A, Tinhofer I, Schneider A, Keilholz U. Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine. Cancer Biol Ther 2010;10:860-4.
121. Raimondi C, Gianni W, Cortesi E, Gazzaniga P. Cancer stem cells and epithelial-mesenchymal transition: Revisiting minimal residual disease. Curr Cancer Drug Targets 2010;10:496-508.
122. Bonnomet A, Brysse A, Tachsidis A, Waltham M, Thompson EW, Polette M, et al. Epithelial-to-mesenchymal transitions and circulating tumor cells. J Mammary Gland Biol Neoplasia 2010;15:261-73.
123. Kaiser J. Cancer's circulation problem. Science (news focus) 2010;327:1072-4.